Mene Pangalos, executive vice-president for BioPharmaceuticals R&D, said the are looking to test two high doses of its experimental vaccine against the new coronavirus in later stage trials.
AstraZeneca's is looking to test two high doses of its experimental vaccine against the new coronavirus in later stage trials rather than focus on approval for single or lower doses of the vaccine, its biopharma chief said on Monday.
"Right now, the safe thing to do is go with two doses, and then we'll start exploring single doses or lower doses," Mene Pangalos, executive vice-president for BioPharmaceuticals R&D, told reporters
Comments
0 comment